Skip to content
MarketScale
‹ Back to IndustriesSciences

The Science Driving Business Growth Across All Industries

In 2012, the Harvard Business Review called the Data Scientist “The Sexiest Job of the 21st Century.” Six years later, people are still not exactly certain what data science is, and how it differs from the statistics field. While data science certainly uses statistics in its analyses, it also uses machine learning, and other similar…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Troy Camplin ·
Share
The Science Driving Business Growth Across All Industries

Key takeaways

01

In 2012, the Harvard Business Review called the Data Scientist “The Sexiest Job of the 21st Century.” Six years later, people are still not exactly certain what data science is, and how it differs from the statistics field.

02

While data science certainly uses statistics in its analyses, it also uses machine learning, and other similar…

In 2012, the Harvard Business Review called the Data Scientist “The Sexiest Job of the 21st Century.” Six years later, people are still not exactly certain what data science is, and how it differs from the statistics field.

While data science certainly uses statistics in its analyses, it also uses machine learning, and other similar scientific methods, processes, algorithms, and systems to extract information from data.

A major component of data science involves trying to find consistent patterns in data to allow scientists to make predictions. Often these patterns are very complex, involving fractal, biotic, and stochastic patterns traditional methods would typically miss. The data can be from a single source or a multitude of sources. The advent of data science has in fact resulted in a call for scientists to “free the data” and make all data available to everyone.

Businesses that use statistical analyses can likely use data science analyses as well. Data on raw materials, physical capital, sales, employment patterns, stocks, commodities trading, and almost anything else imaginable can be analyzed to try to find these complex patterns that often hide information in plain sight. A lot of data sets can look like a bunch of noise, but there are in fact patterns that can with the right analyses be quite easily discovered.

All of these are pattern predictions of course, and pattern predictions will never have the kind of precision enjoyed by physical engineers. Even data science could not give as precise a prediction as the stock market crash taking place in September of 2008, let alone it taking place on Sept. 29 specifically, but it could have predicted that the economy would be in trouble within a year or two of sometime in 2007, given the data available that year. Such information may be enough to save a business.

This is just one potential scenario for how data science can be used to help a business. Each business is different, and unique data will impact businesses in varied ways. Whether it is stock market patterns, future worker shortages in a field, investment patterns, or sales patterns, just to name a few, businesses can use data science to analyze large quantities of data that can help them survive through tough times and to succeed even more when the economy is booming.

For the latest news, videos, and podcasts in the Science Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – twitter.com/ScienceMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

About the author

TC
Troy Camplin

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

TC
Troy Camplin

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512